At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 125 enrolled
Drug / intervention
Canephron® Ndrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Non-randomized, Multicenter, Interventional Study to Investigate the Safety and Efficacy of Canephron® N in the Management of Uncomplicated Urinary Tract Infections (uUTI)
In Brief
A Phase 3 clinical trial evaluating Canephron® N for Urinary Tract Infection. Completed, enrolled 125 participants across 1 site.
Detailed Summary
The objective of the study is to assess safety and impact of a non-antibiotic therapy approach with Canephron® N in the management strategy of uncomplicated lower urinary tract infections (UTIs).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUrinary Tract Infection
CountriesUkraine
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2011
First PostedNov 2011
Primary CompletionMay 2012
Study CompletionAug 2012
TodayJul 2026
First PostedNov 23, 2011
Enrollment StartOct 1, 2011
Primary CompletionMay 1, 2012
Study CompletionAug 1, 2012
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 14.6 years ago
Interventions
Canephron® Ndrug
3x 2 coated tablets/day for 7 days p.o.